Long-Acting ART HIV Treatment Regimens: Key Behavioral Considerations for Stakeholders

This session will focus on key findings and behavioral considerations for long-acting antiretroviral treatment (ART) HIV regimens, given the progress in research, development, and potential approval of these drugs. There will be a brief overview of the ATLAS and FLAIR studies, discussion of the medications, and an outline of the potential impact of the regimens on care delivery models, providers, patients, and payers if they are approved.

Learning Objectives

1. Describe the pharmacology of the long-acting ART.
2. Understand the findings from clinical trials.
3. Discuss implementation approaches for providers, patients, and payers.